Phase I clinical study of Seneca Valley Virus (SVV-001), a replication-competent picornavirus, in advanced solid tumors with neuroendocrine features

Clinical Cancer Research

Volumn 17, Issue 4, 2011, Pages 888-895

  Rudin, Charles M ^a   Poirier, John T ^a   Senzer, Neil N ^b   Stephenson Jr , Joseph ^c   Loesch, David ^d   Burroughs, Kevin D ^e   Reddy, P Seshidhar ^e   Hann, Christine L ^a   Hallenbeck, Paul L ^e  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b Mary Crowley Cancer Research Centers   (United States)

^c Cancer Centers of the Carolinas   (United States)

^d Neotropix Inc ^*

^e JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NEUTRALIZING ANTIBODY; ONCOLYTIC VIRUS; SENECA VALLEY VIRUS; SVV 001; UNCLASSIFIED DRUG; VIRUS ANTIBODY;

ADULT; ADVANCED CANCER; AGED; ARTHRALGIA; ARTICLE; CLINICAL ARTICLE; CLINICAL EVALUATION; CLINICAL FEATURE; COUGHING; DRUG EFFICACY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; FATIGUE; FEMALE; FLU LIKE SYNDROME; HUMAN; IN VIVO STUDY; LUNG SMALL CELL CANCER; MALAISE; MALE; MUSCLE SPASM; MYALGIA; NEUROENDOCRINE TUMOR; PHASE 1 CLINICAL TRIAL; PICORNAVIRUS; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RECOMMENDED DRUG DOSE; SINGLE DRUG DOSE; SMALL CELL CARCINOMA; TOXICITY; TREATMENT RESPONSE; VIRAL CLEARANCE; VIRUS REPLICATION;

ADULT; AGED; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; ONCOLYTIC VIROTHERAPY; PICORNAVIRIDAE; SMALL CELL LUNG CARCINOMA; TREATMENT OUTCOME; VIRAL LOAD;

EID: 79951821209     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-1706     Document Type: Article

References (12)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009;59:225-49.
2. Murray N, Turrisi AT III. A review of first-line treatment for small-cell lung cancer. J Thorac Oncol 2006;1:270-8. (Pubitemid 47181446)
3. Rudin CM, Hann CL, Peacock CD, Watkins DN. Novel systemic therapies for small cell lung cancer. J Natl Compr Canc Netw 2008;6:315-22. (Pubitemid 351488825)
4. Reddy PS, Burroughs KD, Hales LM, Ganesh S, Jones BH, Idamakanti N, et al. Seneca Valley Virus, a systemically deliverable oncolytic picornavirus, and the treatment of neuroendocrine cancers. J Natl Cancer Inst 2007;99:1623-33.
5. Hales LM, Knowles NJ, Reddy PS, Xu L, Hay C, Hallenbeck PL. Complete genome sequence analysis of Seneca Valley virus-001, a novel oncolytic picornavirus. J Gen Virol 2008;89:1265-75.
6. Venkataraman S, Reddy SP, Loo J, Idamakanti N, Hallenbeck PL, Reddy VS. Structure of Seneca Valley Virus-001: an oncolytic picornavirus representing a new genus. Structure 2008;16:1555-61.
7. Venkataraman S, Reddy SP, Loo J, Idamakanti N, Hallenbeck PL, Reddy VS. Crystallization and preliminary X-ray diffraction studies of Seneca Valley virus-001, a new member of the Picornaviridae family. Acta Crystallogr Sect F Struct Biol Cryst Commun 2008;64:293-6. (Pubitemid 351507826)
8. Wadhwa L, Hurwitz MY, Chevez-Barrios P, Hurwitz RL. Treatment of invasive retinoblastoma in a murine model using an oncolytic picornavirus. Cancer Res 2007;67:10653-6. (Pubitemid 350145889)
9. Yamamoto M, Curiel DT. Current issues and future directions of oncolytic adenoviruses. Mol Ther 2009;18:243-50.
10. O'Reilly D, Miller L, Luckow V. Titering Virus Stocks, Baculovirus Expression Vectors: A Laboratory Manual. Oxford: Oxford University Press; 1994
11. Brodsky RA, Jones RJ. Intensive immunosuppression with high dose cyclophosphamide but without stem cell rescue for severe autoimmunity: advantages and disadvantages. Autoimmunity 2008;41:596-600.
12. Perini P, Calabrese M, Rinaldi L, Gallo P. Cyclophosphamide-based combination therapies for autoimmunity. Neurol Sci 29 2008;Suppl 2:S233-4.